Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB trial: Effect of botulinum toxin type A in piriformis syndrome
2023-504427-61-01Phase 4Completed
- Sponsor
- Alrijne Zorggroep
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of botulinum toxin type A in Piriformis syndrome, sponsored by Alrijne Zorggroep. Primary endpoint: Withdrawal follow-up at 12 weeks after test block. Started Nov 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Piriformis syndrome
Beyond the preview
Go deeper on 2023-504427-61-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504427-61-01.